This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Analysis Of The Expanding U.S. Market For Gastrointestinal Disorders Prescription Pharmaceuticals

NEW YORK, April 3, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals

http://www.reportlinker.com/p01083084/Analysis-of-the-Expanding-US-Market-for-Gastrointestinal-Disorders-Prescription-Pharmaceuticals.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

This research service is focused on the major bowel disorders and evaluates the market for oral and injectable prescription pharmaceuticals for the treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). This research service covers the U.S. market from 2009 to 2017, with 2011 as the base year. Included are products on the market, products in development, as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. Disease-specific topics including definitions, diagnosis, disease assessment, and clinical treatment guidelines are also outlined and discussed.

TABLE OF CONTENTS Executive Summary 14Market Overview 20•Definitions 21•Overview of Inflammatory Bowel Disease 23oIncidence and Prevalence of Inflammatory Bowel Disease 24oDiagnosis of Inflammatory Bowel Disease 25oClinical Severity of Inflammatory Bowel Disease 27oAssessment of Disease Activity in IBD Clinical Trials 29oAnatomic Extent of Ulcerative Colitis 31oClinical Guidelines 33•Overview of Irritable Bowel Syndrome 38oDiagnosis of IBS 39oAssessment of Disease Activity in IBS Clinical Trials 40oClinical Trial Design Guidance—IBS 41oClinical Guidelines—IBS 43•Personalized Medicine in Bowel Disorders 44•Key Questions This Study Will Answer 45•Market Overview—Segmentation 46External Challenges: Drivers and Restraints 57Forecast and Trends 69Demand Analysis 84Market Share and Competitive Analysis 87Inflammatory Bowel Disease Prescription Pharmaceuticals Segment 123•5-ASA Subsegment Breakdown 127•Corticosteroid Subsegment Breakdown 138•TNF Inhibitor Subsegment Breakdown 149•Non-TNF Biologicals Subsegment Breakdown 160•Novel Orals Subsegment Breakdown 169Irritable Bowel Syndrome Prescription Pharmaceuticals Segment 177The Last Word (Conclusions and Implications) 188Game-changing Strategies 193Appendix 195

List of ExhibitsMarket Overview —•Total Bowel Disorders Prescription Pharmaceuticals Market: Estimated Incidence and Prevalence of CD and UC, U.S., 2011 24•Total Bowel Disorders Prescription Pharmaceuticals Market: Distinguishing Characteristics of CD and UC, U.S., 2011 25•Total Bowel Disorders Prescription Pharmaceuticals Market: Diagnostic Procedures Used in the Differential Diagnosis of CD and UC, U.S., 2011 26•Total Bowel Disorders Prescription Pharmaceuticals Market: Severity of Ulcerative Colitis Based on the Truelove and Witts Classification, U.S., 2011 27•Total Bowel Disorders Prescription Pharmaceuticals Market: Severity of Crohn's Disease Based on the CDAI, U.S., 2011 28•Total Bowel Disorders Prescription Pharmaceuticals Market: Common Disease Activity Assessment Instruments in Recent Phase 3 UC Trials, U.S., 2011 30•Total Bowel Disorders Prescription Pharmaceuticals Market: Anatomic Extent of Ulcerative Colitis, U.S., 2011 31, 32•Total Bowel Disorders Prescription Pharmaceuticals Market: Clinical Guidelines (Mild to Moderate UC), U.S., 2011 33•Total Bowel Disorders Prescription Pharmaceuticals Market: Clinical Guidelines (Severe UC), U.S., 2011 34•Total Bowel Disorders Prescription Pharmaceuticals Market: Clinical Guidelines (Mild-Moderate) CD, U.S., 2011 35•Total Bowel Disorders Prescription Pharmaceuticals Market: Traditional Clinical Guidelines (Moderate-Severe CD), U.S., 2011 36•Total Bowel Disorders Prescription Pharmaceuticals Market: Modern Clinical Guidelines (Moderate-Severe CD), U.S., 2011 37•Total Bowel Disorders Prescription Pharmaceuticals Market: Rome III Diagnostic Criteria for IBS, U.S., 2011 39•Total Bowel Disorders Prescription Pharmaceuticals Market: Examples of PRO Questions Used as Primary Endpoints in Past IBS Clinical Trials, U.S., 2011 40•Total Bowel Disorders Prescription Pharmaceuticals Market: General Clinical Trial Design Guidance for Sponsors of IBS Clinical Trials, U.S., 2011 41•Total Bowel Disorders Prescription Pharmaceuticals Market: Clinical Trial Design Recommendations for Sponsors of IBS Clinical Trials, U.S., 2011 42•Total Bowel Disorders Prescription Pharmaceuticals Market: Market Segmentation, U.S., 2011 46•Total Bowel Disorders Prescription Pharmaceuticals Market: IBD Market Segmentation, U.S., 2011 47•Total Irritable Bowel Syndrome Therapeutics Market: IBS Market Segmentation, U.S., 2011 52•Total Bowel Disorders Prescription Pharmaceuticals Market: Percent Sales Breakdown by Indication, U.S., 2011 55•Total Bowel Disorders Prescription Pharmaceuticals Market: Percent Sales Breakdown by Drug Class, U.S., 2011 56External Challenges: Drivers and Restraints—Total Bowel Disorders Prescription Pharmaceuticals Market —•Total Bowel Disorders Prescription Pharmaceuticals Market: Key Market Drivers and Restraints, U.S., 2012–2017 58•Total Bowel Disorders Prescription Pharmaceuticals Market: Potential Revenue per Patient for Lifelong IBD Therapy Diagnosed in a Young Patient, U.S., 2011 62•Total Bowel Disorders Prescription Pharmaceuticals Market: Selected Drugs Discontinued for Irritable Bowel Syndrome, U.S., 2011 65•Total Bowel Disorders Prescription Pharmaceuticals Market: Selected Drugs Discontinued for Inflammatory Bowel Disease, U.S., 2011 66Forecasts and Trends—Total Bowel Disorders Prescription Pharmaceuticals Market —•Total Bowel Disorders Prescription Pharmaceuticals Market: IBD Prevalence and Treated Patient Forecast, U.S., 2009-2017 74•Total Bowel Disorders Prescription Pharmaceuticals Market: IBD Prevalence by Indication, U.S., 2009-2017 75•Total Bowel Disorders Prescription Pharmaceuticals Market: IBS Prevalence by Disease Severity and Forecast, U.S., 2009-2017 76-77•Total Bowel Disorders Prescription Pharmaceuticals Market: IBS Prevalence by Indication and Forecast, U.S., 2009-2017 78•Total Bowel Disorders Prescription Pharmaceuticals Market: Range of Reported Disease Prevalence Estimates, U.S., 2011 79Forecasts and Trends—Total Bowel Disorders Prescription Pharmaceuticals Market —•Total Bowel Disorders Prescription Pharmaceuticals Market: Average Annual Cost of Therapy, U.S., 2009-2017 80•Total Bowel Disorders Prescription Pharmaceuticals Market: Revenue Forecast, U.S., 2009-2017 82Demand Analysis—Total Bowel Disorders Prescription Pharmaceuticals Market —•Total Bowel Disorders Prescription Pharmaceuticals Market: IBD Market Penetration, U.S., 2011 85•Total Bowel Disorders Prescription Pharmaceuticals Market: IBS Market Penetration, U.S., 2011 86Market Share and Competitive Analysis—Total Bowel Disorders Prescription Pharmaceuticals Market —•Total Bowel Disorders Prescription Pharmaceuticals Market: Percent of Sales, U.S., 2011 88•Total Bowel Disorders Prescription Pharmaceuticals Market: Absolute Market Share Trend, U.S., 2009-2011 89•Total Bowel Disorders Prescription Pharmaceuticals Market: Percent Market Share Trend, U.S., 2009-2011 90•Total Bowel Disorders Prescription Pharmaceuticals Market: Company Market Share Analysis of Top Four Participants, U.S., 2011 91•Total Bowel Disorders Prescription Pharmaceuticals Market: Competitive Structure, U.S., 2011 92•Total Bowel Disorders Prescription Pharmaceuticals Market: Timeline of Key Events, U.S., 2011 94•Total Bowel Disorders Prescription Pharmaceuticals Market: Comparative Product Profiles of Promising Late-stage Candidates, U.S., 2011 95Market Share and Competitive Analysis—Total Bowel Disorders Prescription Pharmaceuticals Market —•Total Bowel Disorders Prescription Pharmaceuticals Market: Comparative Remission Rates in CD of Selected Marketed and Late-stage Drugs, U.S., 2011 96-97•Total Bowel Disorders Prescription Pharmaceuticals Market: Comparative Remission Rates in UC of Selected Marketed and Late-stage Drugs, U.S., 2011 98-99•Total Bowel Disorders Prescription Pharmaceuticals Market: Number of Drugs per Class by Stage of Development—Oral and Injectable Therapies for IBD, U.S., 2011 101•Total Bowel Disorders Prescription Pharmaceuticals Market: Number of Drugs per Class by Stage of Development—Topical Therapies for IBD, U.S., 2011 102•Total Bowel Disorders Prescription Pharmaceuticals Market: Number of IBD Drugs per Class by Stage of Development, U.S., 2011 103•Total Bowel Disorders Prescription Pharmaceuticals Market: IBD Marketed Product Analysis, U.S., 2011 104-107•Total Bowel Disorders Prescription Pharmaceuticals Market: IBD Late-stage Product Analysis, U.S., 2011 108-109•Total Bowel Disorders Prescription Pharmaceuticals Market: IBD Pipeline Analysis, U.S., 2011 110-117•Total Bowel Disorders Prescription Pharmaceuticals Market: Number of IBS Drugs per Class by Stage of Development, U.S., 2011 118•Total Bowel Disorders Prescription Pharmaceuticals Market: IBS Marketed Product Analysis, U.S., 2011 119Market Share and Competitive Analysis—Total Bowel Disorders Prescription Pharmaceuticals Market —•Total Bowel Disorders Prescription Pharmaceuticals Market: IBS Late-stage Product Analysis, U.S., 2011 120•Total Bowel Disorders Prescription Pharmaceuticals Market: IBS Pipeline Analysis, U.S., 2011 121-122Inflammatory Bowel Disease Prescription Pharmaceuticals Segment •Inflammatory Bowel Disease Prescription Pharmaceuticals Market: Percent Sales Breakdown by Drug Class, U.S., 2011 126•Inflammatory Bowel Disease Prescription Pharmaceuticals Market: Percent Patient Share Breakdown by Drug Class, U.S., 2011 126 5-ASA Subsegment Breakdown —•5-ASA Subsegment Percent Sales Breakdown, U.S., 2011 128•5-ASA Subsegment: Treated Patient Forecast, U.S., 2009-2017 130•5-ASA Subsegment: Average Annual Cost of Therapy, U.S., 2009-2017 132•5-ASA Subsegment: Revenue Forecast, U.S., 2009-2017 134•5-ASA Subsegment: Percent of Sales, U.S., 2011 136•5-ASA Subsegment: Company Market Share Analysis of Top Two Participants, U.S., 2011 137Corticosteroid Subsegment Breakdown —•Corticosteroid Subsegment Percent Sales Breakdown, U.S., 2011 139•Corticosteroid Subsegment: Treated Patient Forecast, U.S., 2009-2017 141•Corticosteroid Subsegment: Average Annual Cost of Therapy, U.S., 2009-2017 143•Corticosteroid Subsegment: Revenue Forecast, U.S., 2009-2017 145•Corticosteroid Subsegment: Percent of Sales, U.S., 2011 147•Corticosteroid Subsegment: Company Market Share Analysis of Participants, U.S., 2011 148TNF Inhibitor Subsegment Breakdown —•TNF Inhibitor Subsegment: Percent Sales Breakdown, U.S., 2011 150•TNF Inhibitor Subsegment: Treated Patient Forecast, U.S., 2009-2017 152•TNF Inhibitor Subsegment: Average Annual Cost of Therapy, U.S., 2009-2017 154•TNF Inhibitor Subsegment: Revenue Forecast, U.S., 2009-2017 156•TNF Inhibitor Subsegment: Percent of Sales, U.S., 2011 158•TNF Inhibitor Subsegment: Company Market Share Analysis of Participants, U.S., 2011 159Non-TNF Biologicals Subsegment Breakdown —•Non-TNF Biologicals Subsegment: Percent Sales Breakdown, U.S., 2011 161•Non-TNF Biologicals Subsegment: Treated Patient Forecast, U.S., 2009-2017 163•Non-TNF Biologicals Subsegment: Average Annual Cost of Therapy, U.S., 2009-2017 165•Non-TNF Biologicals Subsegment: Revenue Forecast, U.S., 2009-2017 167Novel Orals Subsegment Breakdown —•Novel Orals Subsegment: Percent Sales Breakdown, U.S., 2011 170•Novel Orals Subsegment: Percent Sales Breakdown, U.S., 2017 170•Novel Orals Subsegment: Treated Patient Forecast, U.S., 2009-2017 171•Novel Orals Subsegment: Average Annual Cost of Therapy, U.S., 2009-2017 173•Novel Orals Subsegment: Revenue Forecast, U.S., 2009-2017 175Irritable Bowel Syndrome Segment Breakdown —•IBS Segment: Percent Sales Breakdown, U.S., 2011 180•IBS Segment: Treated Patient Forecast, U.S., 2009-2017 182•IBS Segment: Average Annual Cost of Therapy, U.S., 2009-2017 184•IBS Segment: Revenue Forecast, U.S., 2009-2017 186

To order this report: Analysis of the Expanding U.S. Market for Gastrointestinal Disorders Prescription Pharmaceuticals

Contact Clare: clare@reportlinker.comUS:(339) 368 6001Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs